Explore the latest clinical research, emerging therapies, and evidence-based insights in glaucoma management. Stay informed about modern treatment strategies, drug innovations, microbiome research, and technological advances shaping the future of ophthalmology and vision preservation.
Prostaglandin analogs are first-line therapy for glaucoma; however, many patients require additional agents to achieve adequate intraocular pressure (IOP) control, and multiple eye drops often reduce adherence and clinical outcomes. The fixed combination of latanoprost 0.005% and timolol 0.5% (LTFC), introduced in 2001, simplifies dosing, improves adherence and quality of life, and provides greater IOP reduction than monotherapy and some other combination regimens, making it an effective option for patients insufficiently controlled on monotherapy.
Read MoreA review published in BMC Ophthalmology indicates that the fixed-dose combination of latanoprost (0.005%) and timolol maleate (0.5%) provides enhanced intraocular pressure (IOP) reduction compared with monotherapy or multidrug regimens. This combination therapy may also improve patient adherence and overall quality of life (QOL) by simplifying the treatment protocol. The findings emphasize the ongoing clinical importance of streamlined therapeutic strategies for patients with glaucoma who do not achieve sufficient IOP control with a single-agent approach.
Read MoreThe glaucoma development pipeline is steadily progressing, underscoring continued commitment to innovation in both drug discovery and delivery systems. In addition to established topical treatments, the evolving pipeline features compounds targeting novel molecular pathways, sustained-release formulations, and device-based modalities aimed at achieving sustained and reliable intraocular pressure control. These emerging pharmacologic and technological interventions represent important advancements within the current glaucoma pipeline and merit careful clinical evaluation.
Read MoreTopical ocular antihypertensive agents reduce intraocular pressure (IOP) through a limited number of established pharmacologic mechanisms, primarily by decreasing aqueous humor production or enhancing aqueous outflow. Prostaglandin analogs are widely regarded as first-line therapy for glaucoma and ocular hypertension due to their robust efficacy and convenient dosing schedule. Although currently available topical medications are generally well tolerated, they are frequently associated with ocular surface disturbances. Prostaglandin analogs exhibit class-specific adverse effects, whereas beta-adrenergic blockers and alpha-adrenergic agonists may produce significant systemic adverse events, some of which can be potentially life-threatening.
Read MoreIn a randomized, crossover, single-center study involving 34 patients with primary open-angle glaucoma or ocular hypertension, preservative-free timolol (PF-timolol) administered twice daily was compared with once-daily preserved timolol (P-timolol) over two 6-week treatment periods. PF-timolol demonstrated a significantly greater intraocular pressure (IOP) reduction in the right eye at week 6; however, by week 12, IOP reduction was comparable between groups. Ocular surface parameters favored PF-timolol, with significant improvements in tear film breakup time and superficial punctate keratopathy scores, while systemic vital signs and patient-reported symptoms were similar across treatments. Overall, PF-timolol provided equivalent long-term efficacy with superior ocular surface safety, supporting its use particularly in patients sensitive to preservatives.
Read MoreOcular surface disease (OSD) represents a common but often underrecognized complication in glaucoma management. The substantial overlap between glaucoma and dry eye disease (DED) significantly influences therapeutic outcomes, negatively affecting patient comfort, treatment adherence, and overall disease control.
Read MoreSustained innovation in ophthalmic pharmacotherapy and drug-delivery systems remains essential to address the growing global burden of visual impairment. The World Health Organization estimates that at least 2.2 billion people worldwide are affected by vision impairment, with approximately 1 billion cases considered preventable or inadequately treated, resulting in substantial socioeconomic impact. Chronic ocular conditions—including glaucoma, age-related macular degeneration, and diabetic retinopathy—are major causes of severe vision loss, while disorders such as ocular surface disease, including dry eye disease, blepharitis, meibomian gland dysfunction, and neurotrophic keratitis, significantly compromise visual function and patient quality of life.
Read MoreGlaucoma, a leading cause of irreversible blindness, is increasingly linked not only to elevated intraocular pressure but also to alterations in ocular and gut microbiota. A 2025 PRISMA-based review of 14 studies identified distinct microbial shifts in glaucoma patients, including reduced Corynebacterium mastiditis and Actinobacteria and increased Firmicutes and Proteobacteria. Benzalkonium chloride exposure and coexisting dry eye disease were associated with greater dysbiosis. These findings suggest a potential contributory role of microbiota imbalance in glaucoma pathogenesis and highlight opportunities for microbiome-based risk assessment and therapeutic strategies.
Read MoreAs ophthalmology advances toward 2026, emerging technologies—including artificial intelligence (AI), home-based monitoring systems, and sustained-release drug delivery platforms—are poised to transform glaucoma detection, monitoring, and treatment. However, their integration into routine practice will depend on workflow compatibility, cost-effectiveness, and patient acceptance. In an expert discussion with the Eye Care Network, Joel S. Schuman, MD, FACS, of Wills Eye Hospital highlighted near-term innovations likely to enter clinical practice, implementation challenges, and experimental strategies that may shape glaucoma care in the coming years.
Read MoreGlaucoma is a group of progressive optic neuropathies characterized by damage to the optic nerve, often developing slowly and without early symptoms, leading to irreversible peripheral vision loss—hence its description as a “silent thief of sight.” Although lost vision cannot typically be restored, early diagnosis and consistent management can slow or stabilize progression. The cornerstone of treatment is lowering intraocular pressure (IOP), the most established strategy for protecting optic nerve function. Modern glaucoma care focuses on timely detection, individualized target IOP setting, and ongoing monitoring to optimize long-term visual outcomes.
Read MoreGlaucoma, long termed the “silent thief of sight,” has traditionally required lifelong daily eye drops for disease control. Advances in research and technology now offer longer-lasting, more effective treatment options that reduce treatment burden and improve patient convenience. At North Toronto Eye Care, specialists provide personalized, innovative glaucoma management strategies that may minimize or eliminate the need for daily topical therapy.
Read MoreLatanoprost, developed through the pioneering work of Laszlo Bito and approved in 1996, has become a first-line therapy for lowering intraocular pressure and preventing optic nerve damage in glaucoma. Although it has preserved vision for millions, ongoing research by experts such as Simon John at Columbia University Vagelos College of Physicians and Surgeons highlights that disease progression can still occur in some patients despite normal pressure, underscoring the need for further therapeutic advancements.
Read MoreProphylactic use of fixed-combination dorzolamide–timolol was evaluated in a retrospective review of 519 eyes undergoing phacoemulsification between September 2023 and April 2024. Patients receiving immediate postoperative dorzolamide–timolol (n=286) were compared with controls without prophylaxis (n=233). Although preoperative intraocular pressures (IOP) were similar between groups, mean postoperative day 1 IOP was significantly lower in the prophylaxis group (13.7 vs. 18.4 mm Hg; p <0.0001), with fewer IOP spikes ≥28 mm Hg (1.7% vs. 9.9%; p<0.0001). The effect was independent of glaucoma status, while open-angle glaucoma, ocular hypertension, and narrow angles were identified as significant risk factors for postoperative IOP spikes. These findings support the effectiveness of prophylactic dorzolamide–timolol in reducing early IOP elevations after cataract surgery.
Read MoreThis phase III trial evaluated the non-inferiority of a preservative-free fixed combination of timolol, dorzolamide, and brimonidine versus preserved fixed combination therapy or concomitant triple therapy in 80 eyes of 43 patients with uncontrolled primary open-angle glaucoma over 90 days. All groups achieved comparable intraocular pressure reductions at 9:00 a.m. (−7.7 to −8.3 mmHg) and 11:00 a.m. (−9.3 to −9.8 mmHg), with no significant differences between treatments. The preserved fixed-combination group demonstrated increased conjunctival hyperemia at early follow-up, while tolerability, ocular surface findings, and overall safety were similar across groups. The preservative-free formulation provided effective IOP control with good tolerability and may improve adherence in patients requiring multiple medications.
Read MoreThis prospective, multicenter, open-label study assessed the safety and efficacy of preservative-free dorzolamide 2%–timolol 0.5% in 30 patients with dry eye disease previously treated with benzalkonium chloride–containing therapy. After transition and 24-week follow-up, 25 patients completed the study. Ocular Surface Disease Index scores significantly improved (21.5 to 12.5; p < 0.001), with 52% achieving complete symptom resolution. Corneal staining and conjunctival hyperemia decreased substantially, tear break-up time increased (5.0 to 7.0 seconds; p < 0.01), and intraocular pressure was maintained with a modest reduction (−1 mmHg; p < 0.01). Most patients preferred the preservative-free formulation. These findings indicate that switching to preservative-free therapy improves ocular surface health and tolerability while maintaining effective IOP control.
Read MoreDry eye disease (DED) affects approximately 5–15% of individuals and is characterized by redness, burning or stinging sensations, and ocular fatigue that may impair activities such as reading or screen use. It occurs when tear production is insufficient or when tear film composition is unstable, compromising ocular surface lubrication and protection. Contributing factors include allergies, autoimmune disorders, hormonal changes, and aging. If inadequately managed, DED can increase susceptibility to infection and cause epithelial damage, potentially leading to visual impairment over time.
Read MoreJanuary, recognized as Glaucoma Awareness Month, highlights the critical importance of early detection of glaucoma—a leading cause of irreversible blindness affecting over 3 million people in the United States. Often termed the “silent thief of sight,” glaucoma typically progresses without noticeable symptoms while causing gradual optic nerve damage. Albert S. Khouri, professor of ophthalmology and director of the glaucoma service at Rutgers New Jersey Medical School, emphasizes the need for routine eye examinations, identification of risk factors, and timely intervention to prevent vision loss, while outlining ongoing advancements in glaucoma management and treatment.
Read More